Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput flow cytometry with high-content cyclic immunofluorescence for the early identification of target candidates for cellular immunotherapy. Within this webinar, we aim to guide the viewers through our most recently published scientific findings and related cutting-edge tools, ranging from the preparation of primary and xenografted tumor specimens to the comprehensive antigen screening and deep phenotyping.
 Schäfer, D., Tomiuk, S., Küster, L.N. et al. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 12, 1453 (2021). https://doi.org/10.1038/s41467-021-21774-4
1. Breakdown a problem of solid tumor CAR T cell therapies is that most identified tumor-associated antigens are also expressed in healthy tissue.
2. Explain how we systematically screened for PDAC CAR targets by high-throughput flow cytometry followed by high-content immunoflourescent imaging.
3. Duscuss how CD318, TSPAN8 and CD66c were identified as potential targets for CAR T cell based immunotherapy of PDAC.